更新于：2024-11-01

Farwaniya Hospital

更新于：2024-11-01

概览

管线布局

概览

关联

项与 Farwaniya Hospital 相关的临床试验

NCT06539663 / Completed临床2/3期IIT

The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients

Case series of 5 ICU patients in Farwaniya Hospital who developed exposure keratitis and a subsequent small corneal perforation between April 2022 and April 2024.
The investigators highlight the non-surgical role of OmniLenz® in the treatment of small corneal perforations secondary to exposure keratitis. The inclusion criteria were corneal perforation less than 1mm in size, positive culture & sensitivity results and showing initial improvement on topical antibiotic eye drops.

开始日期2022-04-10

申办/合作机构

Farwaniya Hospital

NCT05720715 / Completed临床4期IIT

Evaluation of the Safety and Efficacy of Cyclosporine A 0.05% Eye Drops in Management of Non- Necrotizing Herpetic Stromal Keratitis; a Prospective Controlled Clinical Trial

Objective: To compare the additive effect of topical cyclosporine A 0.05% eye drops to prednisolone eye drops, with topical prednisolone acetate 1% eye drops alone in treatment of herpetic stromal keratitis.
Methods: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.
Group B: receive topical prednisolone with placebo eye drops (tear replacement).
The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.

开始日期2022-01-01

申办/合作机构

Farwaniya Hospital

NCT05618522 / CompletedN/AIIT

Clinical Outcomes of Low Temperature Vacuum-dehydrated Amnion Membrane (Omnigen) in Treatment of Acute Chemical Eye Injuries

evaluation of the role of Omnigen in acute chemical eye injuries

开始日期2021-07-01

申办/合作机构

Farwaniya Hospital

100 项与 Farwaniya Hospital 相关的临床结果

登录后查看更多信息

0 项与 Farwaniya Hospital 相关的专利（医药）

登录后查看更多信息

377

项与 Farwaniya Hospital 相关的文献（医药）

2024-12-01·Resuscitation Plus

Out-of-hospital cardiac arrest in Bahrain: National retrospective cohort study

Article

作者: Ali AlShaaban, Mustafa ; Al Qassim, Ghada ; Husain Abuzeyad, Feras ; Chomayil, Yasser ; Fuad Mubarak, Abdulla ; Mohammed Ali Mansoor, Naser ; Alqasem, Leena ; Sami Alserdieh, Faisal ; Murad Ashraf, Muhammad ; Zafar, Hamid ; Adel AlAseeri, Danya ; Minwer Saad Albashtawi, Emad ; Farooq, Moonis ; Zuhair Salman, Ahmed ; Ahmed Shams, Maryam

AimThere is limited research on Out-of-hospital cardiac arrest (OHCA) in the Gulf Cooperation Council (GCC) and especially in Bahrain. This is the first study to describe the incidence, characteristics, and outcomes of OHCA in Bahrain.MethodsThis was a retrospective national observational study on OHCA patients in Bahrain using the Utstein framework for resuscitation. Data was collected between 1st July 2022 to 30th June 2023 from the electronic medical records of the only three governmental hospitals emergency departments (EDs) and National Ambulance (NA).ResultsThe annual incidence of OHCA attended by (Emergency Medical Services) EMS was nearly 21 per 100,000 population. The majority were males (n = 228, 68.8 %) with median age of 65 years (IQR=49-78). Most OHCA cases were witnessed (n = 265, 81 %), with (n = 247, 76 %) happened at home/residence. Rates for bystander CPR was low (n = 122, 36.8 %) and bystander automated external defibrillator (AED) was not performed in any of the cases. The OHCA cases transported by the NA was (n = 314, 94.8 %), with median response time of 9 min (IQR=7-12). However, only (n = 20, 6.0 %) were witnessed by EMS, and (n = 7, 2.1 %) received EMS defibrillation for shockable rhythms. First monitored rhythms included shockable rhythm in (n = 28, 8.5 %) versus non-shockable rhythm in (n = 303, 91.5 %). In the EDs, return of spontaneous circulation was achieved in (n = 60, 18.1 %) cases. But survival rate to hospital discharge at 30-day was (n = 4, 1.2 %) and survival rate to hospital discharge with good neurological outcomes was (n = 0, 0 %). Conclusion: In Bahrain the estimated annual incidence of OHCA is 21 individuals per 100,000 population, with a very low survival rate. Solutions should focus on community-level CPR and AED training, evaluating OHCA care provided by EMS, and establishing OHCA registry.

2024-10-01·Arab Journal of Urology

Impact of varicocele repair on semen parameters and spontaneous pregnancy: An endless debate put to rest

Article

作者: Saleh, Ramadan ; Harraz, Ahmed ; Shah, Rupin ; Toprak, Tuncay ; Agarwal, Ashok

There has been much controversy about the true value of varicocele repair for improving fertility and the chances of natural conception. This review summarizes the latest research findings, current professional societies' recommendations, and the conclusions of recent systematic reviews and meta-analyses. The current evidence suggests a positive role for varicocele repair in improving basic sperm parameters and increasing the likelihood of natural pregnancy.

2024-09-06·Medical Mycology

A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole

Review

作者: Chen, Sharon C-A ; Alfouzan, Wadha Ahmed ; Thompson, George R ; Izumikawa, Koichi ; Maertens, Johan ; Colombo, Arnaldo L

AbstractGlobal epidemiological data show that the incidence of invasive fungal disease (IFD) has increased in recent decades, with the rising frequency of infections caused by Aspergillus and Mucorales order species. The number and variety of patients at risk of IFD has also expanded, owing in part to advances in the treatment of hematologic malignancies and other serious diseases, including hematopoietic stem cell transplantation (HCT) and other therapies causing immune suppression. Isavuconazonium sulfate (active moiety: isavuconazole) is an advanced-generation triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis that has demonstrated activity against a variety of yeasts, moulds, and dimorphic fungi. While real-world clinical experience with isavuconazole is sparse in some geographic regions, it has been shown to be effective and well tolerated in diverse patient populations, including those with multiple comorbidities who may have failed to respond to prior triazole antifungal therapy. Isavuconazole may be suitable for patients with IFD receiving concurrent QTc-prolonging therapy, as well as those on venetoclax or ruxolitinib. Data from clinical trials are not available to support the use of isavuconazole prophylactically for the prevention of IFD or for the treatment of endemic IFD, such as those caused by Histoplasma spp., but real-world evidence from case studies suggests that it has clinical utility in these settings. Isavuconazole is an option for patients at risk of IFD, particularly when the use of alternative antifungal therapies is not possible because of toxicities, pharmacokinetics, or drug interactions.

100 项与 Farwaniya Hospital 相关的药物交易

登录后查看更多信息

100 项与 Farwaniya Hospital 相关的转化医学

登录后查看更多信息